MAIA Biotechnology activated its first U.S. clinical site for the Phase 2 THIO‑101 expansion trial at Summit Medical Group in New Jersey, marking the company’s entry into the U.S. patient population for this advanced non‑small cell lung cancer (NSCLC) program.
The company plans to open four additional U.S. sites in 2026, expanding the trial’s reach from its existing 44 international sites in six countries to a broader U.S. presence that is expected to accelerate patient enrollment and data collection.
The expansion is supported by a $2.3 million grant from the National Institutes of Health, underscoring the scientific promise of the program and providing essential resources for U.S. enrollment.
Ateganosine (THIO) is a first‑in‑class telomere‑targeting agent being evaluated in two arms—monotherapy and sequencing with cemiplimab (Libtayo®). The program has FDA Fast Track designation for advanced NSCLC. Eight patients treated with the sequenced arm have achieved overall survival beyond two years, with one patient reaching 33 months and four exceeding 30 months. "We are thrilled to activate the expansion of our Phase 2 THIO‑101 trial in the U.S., bringing our novel treatment to our country's broad underserved NSCLC patient population. Every year, we estimate approximately 50,000 patients resistant to chemo and CPIs alone advance to third‑line NSCLC in the U.S. The medical need is extensive," said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA. "We are proud to be the first U.S. site to offer patients access to MAIA's innovative THIO‑101 expansion trial and contribute to advancing a promising new treatment strategy in lung cancer," added Charles J. Kim, M.D., Summit Health oncologist and principal investigator. "It's very encouraging to see such outstanding survival from these patients extending beyond our 24‑month trial protocol and without any subsequent treatment. OS surpassing two‑years bodes well as we continue to monitor patients in our ongoing Phase 3 pivotal trial and in THIO‑101 Part C. These results illuminate ateganosine's valuable role in targeting telomeres to eliminate NSCLC tumor cells and support this treatment—ateganosine sequenced by a CPI—as a potential breakthrough therapeutic option for NSCLC.", Vitoc continued.
The U.S. expansion is expected to speed enrollment, enhance data robustness, and bring the program closer to potential regulatory approval. MAIA’s recent $33 million capital raise in March 2026 and its strong cash position—market capitalization of $86.15 million, cash exceeding debt, and a current ratio of 1.66—provide a solid financial foundation for continued development.
TipRanks has issued a "Buy" rating with a $14.00 price target for MAIA as of April 16, 2026, reflecting investor confidence in the company’s clinical progress and financial position.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.